Results 111 to 120 of about 28,066 (219)
British Journal of Pharmacology, EarlyView.The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli +6 more
wiley +1 more source
Purpose of review: In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Asim, Ramsha +2 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest +3 more
wiley +1 more source
Role of PCSK9 beyond liver involvement
, 2015 International audiencePURPOSE OF REVIEW: Proprotein convertase subtilisin kexin type 9 (PCSK9) acts as an endogenous natural inhibitor of the LDL receptor pathway, by targeting the receptor to lysosomes for degradation.
Si-Tayeb, Karim +2 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Genetic clusters related to Type 2 diabetes (T2D) have differential impact on cardiovascular diseases (CVDs), although the underlying mechanisms, such as proteomic perturbation, remain unexplored. We conducted a network Mendelian randomisation (MR) study to identify proteomic mediators linking T2D genetic clusters and CVDs.
Shuang Liao +4 more
wiley +1 more source
Potential of PCSK9 as a new target for the management of LDL cholesterol
, 2015 Guiliana Mombelli, Samuela Castelnuovo, Chiara PavanelloCardiovascular Department, Dyslipidemia Center, Azienda Ospedaliera Niguarda Cà Granda, Milan, ItalyAbstract: A large proportion of patients at high risk for cardiovascular disease continue ...
Mombelli G, Castelnuovo S, Pavanello C
core
Anti-PCSK9 vaccination does not activate PCSK9-specific T cells.
, 2014 ELISpot analysis for INF-γ-releasing splenocytes isolated from C57BL/6 (H-2Db) mice. (A) naϊve mice (negative control). (B) mice immunized with KLH alone. (C) mice immunized with anti-PCSK9 vaccine.
Guenther Staffler (669364) +11 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding +4 more
wiley +1 more source
Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Journal of Internal Medicine, EarlyView.Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello +3 more
wiley +1 more source
Journal of Periodontal Research, EarlyView.This systematic review evaluated drug‐target Mendelian randomisation studies on periodontitis. Twelve studies identified host‐response‐related targets mainly involved in inflammatory, complement, and immune pathways. Although some targets were linked to existing drugs, the evidence remains preliminary and heterogeneous, requiring replication and ...
Luigi Nibali +4 more
wiley +1 more source